Combining Acitretin and Efalizumab in the Therapy of Chronic Plaque Psoriasis
Status:
Unknown status
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
It is a phase IV multicentric, placebo-controlled, clinical trial investigating the efficacy
and safety of acitretin combined to efalizumab in the therapy of chronic plaque psoriasis.
PASI 75 at week 24 will be the primary end point. PASI 75 at week 12, and PASI 50 at week 24
will be the secondary end points. Safety measures will be the monitoring of serum parameters
including AST; ALT; gammaGT; creatinine; cholesterol and triglycerides.